登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JAMA，4月3日，Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-06

  • Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers

    Chirag Bavishi, MD, MPH1; Thomas M. Maddox, MD, MSc2,3; Franz H. Messerli, MD4,5,6

    Author Affiliations Article Information

    JAMA Cardiol. Published online April 3, 2020. doi:10.1001/jamacardio.2020.1282

    The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already surpassed the combined mortality inflicted by the severe acute respiratory syndrome (SARS) epidemic of 2002 and 2003 and the Middle East respiratory syndrome (MERS) epidemic of 2013. The pandemic is spreading at an exponential rate, with millions of people across the globe at risk of contracting SARS-CoV-2. Initial reports suggest that hypertension, diabetes, and cardiovascular diseases were the most frequent comorbidities in affected patients, and case fatality rates tended to be high in these individuals. In the largest Chinese study to date,1 which included 44?672 confirmed cases, preexisting comorbidities that had high mortality rates included cardiovascular disease (10.5%), diabetes (7.3%), and hypertension (6.0%). Patients with such comorbidities are commonly treated with renin angiotensin system blockers, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).

  • 原文来源：https://jamanetwork.com/journals/jamacardiology/fullarticle/2764299?resultClick=1
127浏览量
原文链接
相关报告

  • 《Nature，4月3日，Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-04
    • Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic Andrew M. South, Laurie Tomlinson, Daniel Edmonston, Swapnil Hiremath & Matthew A. Sparks Nature Reviews Nephrology (2020) The current COVID-19 pandemic is associated with unprecedented morbidity and mortality. Early reports suggested an association between disease severity and hypertension but did not account for sources of confounding. However, the responsible virus — SARS-CoV-2 — gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the need to understand the relationship between the virus and the renin–angiotensin system (RAS) and how this might be affected by RAS inhibitors.
    203浏览量
    原文链接

  • 《JAMA，3月24日，COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers What Is the Evidence?》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-25
    • COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers What Is the Evidence? Ankit B. Patel, MD, PhD1; Ashish Verma, MBBS1 JAMA. Published online March 24, 2020. doi:10.1001/jama.2020.4812 Coronavirus disease 2019 (COVID-19) is a current pandemic infection caused by a positive-sense RNA virus named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The particularly infectious capacity of the virus, along with mortality rates ranging from 1% to above 5%, has raised concerns across the globe.1 Older patients with comorbid conditions including pulmonary disease, cardiac disease, kidney disease, diabetes, and hypertension have been associated with even higher mortality rates, suggesting particularly susceptible populations.
    174浏览量
    原文链接